With the growth of science, traditional Sanger sequencing didn’t meet new requirements of low priced, high throughput and fast in speed.
Recent years, with all the discovery and promotion of second-generation sequencing technology, the gene sequencing speed has grown greatly while achieving an amazing decline in costs, making large-scale using genome sequencing possible. Now, the price tag on personal whole genome sequencing is all about 5,000$, and is also expected to decreased to lower than $ 1,000 within the next few years.
The rapid growth of sequencing technology will promote the large accumulation of DNA sequencing data, associated with the accumulation from the corresponding individual diseases, signs as well as other data while doing so. When we accumulate enough data, the best way to understand these data will likely be critical. On the micro level, generations of molecular biologists’ checking the effects of apparent biological traits genes exert on utilizing technologies like gene knockout have elected breakthroughs in most crucial aspects. On the macro level, statistics and also other data analysis techniques are unveiled in study their bond between gene sequences and biological phenotype. The accumulation of basic scientific research gradually brings breakthroughs in clinical applications.
There are actually two types of clinical applications mainly, one is aimed at disease screening of ordinary people. It infers people’s future perils associated with getting cancer by measuring the known genes connected with a disease loci. The other targets the diagnosis cancer as well as other deadly diseases. It finds in the series of drugs or plans the most efficient one for several patients by testing the loci of certain genes.
Data from BBC research indicates that total global gene sequencing market increased from $ 7.941million in 2007 to $ 4.5 billion in 2013, and definately will reach $ 11.7 billion in of 2018 using the CAGR nearly 21.2%.
Currently, the marketplace of de novo sequence platform is especially taken by a number of major manufacturers, for example the Illumina, Ion Torrent / Life Technologies (was the investment of Thermo Fisher in 2014), 454 Life Sciences / Roche, etc.
Under this kind of circumstance, the next generation sequencing technology (second-generation sequencing) appears. As an emerging industry, the next-generation sequencing technology can be applied in clinical testing like antibody discovery, health industry, industrial and agricultural using gene-oriented study together with scientific research and development.